LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Home・Akcijų sąrašas・Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

719.66 -0.26

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

708.04

Max

729.83

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-117M 727M
Pardavimai	-279M 3.6B
P/E Sektoriaus vid.	17.393 51.415
Pelnas, tenkantis vienai akcijai	9.47
Dividendų pajamingumas	0.5
Pelno marža	20.17
Darbuotojai	15,343
EBITDA	-234M 967M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+22.32% upside

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	0.50% 2.34%
Kitas uždarbis	2026-07-31

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-3.3B 75B
Ankstesnė atidarymo kaina	719.92
Ankstesnė uždarymo kaina	719.66

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

542.44 / 599.76 Palaikymas ir pasipriešinimas

Regeneron Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-01 11:33; UTC

Uždarbis

Regeneron 2Q Revenue, Adjusted EPS Top Estimates

2026-04-29 12:01; UTC

Uždarbis

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

2026-04-23 21:48; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Shares Up on Trump Drug Pricing Deal -- Barrons.com

2026-03-11 11:02; UTC

Rinkos pokalbiai

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

2025-12-14 08:30; UTC

Įsigijimai, susijungimai, perėmimai

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

2025-08-01 13:16; UTC

Uždarbis

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

2025-08-01 12:40; UTC

Uždarbis

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

2025-08-01 10:41; UTC

Uždarbis

Regeneron Now Sees 2025 Adjusted R&D $5.1B-$5.2B; Had Seen $5B-$5.2B >REGN

2025-08-01 10:41; UTC

Uždarbis

Regeneron Now Sees 2025 Capital Spending $880M-$950M; Had Seen $850M-$950M >REGN

2025-08-01 10:40; UTC

Uždarbis

Regeneron Now Sees 2025 Adjusted Gross Margin on Net Product Sales About 86%; Had Seen 86%-87% >REGN

2025-08-01 10:38; UTC

Uždarbis

Regeneron: Odronextamab Application Also Impacted by Site Inspection >REGN

2025-08-01 10:37; UTC

Uždarbis

Regeneron Gets FDA Complete Response Letter for Odronextamab in Follicular Lymphoma >REGN

2025-08-01 10:35; UTC

Uždarbis

Regeneron: Anticipate Expeditious Resolution of Filling Issues for Eylea HD >REGN

2025-08-01 10:34; UTC

Uždarbis

Regeneron Cites Observations From FDA General Site Inspection at Filler for Eylea HD >REGN

2025-08-01 10:33; UTC

Uždarbis

Regeneron Sees FDA Approvals Delayed for Eylea HD Indications With August Target Actio Dates >REGN

2025-08-01 10:32; UTC

Uždarbis

Regeneron Pharma: About 45 Product Candidates in Clinical Development >REGN

2025-08-01 10:31; UTC

Uždarbis

Regeneron Pharma 2Q Eylea HD, Eylea U.S. Net Sales Fell 25% to $1.15B >REGN

2025-08-01 10:31; UTC

Uždarbis

Regeneron Pharma: 2Q Dupixent Global Net Sales Recorded by Sanofi Rose 22% to $4.34B >REGN

2025-08-01 10:30; UTC

Uždarbis

Regeneron Pharma 2Q Adj EPS $12.89 >REGN

2025-08-01 10:30; UTC

Uždarbis

Regeneron Pharma 2Q Rev $3.68B >REGN

2025-08-01 10:30; UTC

Uždarbis

Regeneron Pharma 2Q EPS $12.81 >REGN

2025-08-01 10:30; UTC

Uždarbis

Regeneron Pharma 2Q Net $1.39B >REGN

2025-06-13 21:42; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

2025-06-13 20:45; UTC

Įsigijimai, susijungimai, perėmimai

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

2025-06-13 20:34; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- Update

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

2025-06-13 20:14; UTC

Įsigijimai, susijungimai, perėmimai

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

2025-06-05 01:41; UTC

Įsigijimai, susijungimai, perėmimai

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

2025-05-30 08:58; UTC

Karštos akcijos

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

Akcijų palyginimas

Kainos pokytis

Regeneron Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

22.32% į viršų

12 mėnesių prognozė

Vidutinis 884.89 USD 22.32%

Aukščiausias 1,057 USD

Žemiausias 762 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Regeneron Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

Pirkti

Laikyti

Parduoti

Remiantis 19 analitikų, pateikusių Regeneron Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

542.44 / 599.76Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.